ClinicalTrials.gg
Sign In

Severe Dengue clinical trials

The registry lists 65 studies for Severe Dengue across more than 10 countries. 5 are recruiting or about to start. 51 of them are mainly about Severe Dengue (how this is decided). Per ClinicalTrials.gov, last updated 2026-08-06.

Get an email when these change. Save the Severe Dengue studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
53
Recruiting
4
Active, not recruiting
3
Status unknown
3
Not yet recruiting
1
Terminated
1

Phase

Phase 2
21
Phase 1
16
Phase 3
13
Phase 4
1

Where

United States
18
Thailand
7
Colombia
7
Philippines
6
Mexico
6
Puerto Rico
5

Who runs them

Sanofi Pasteur, a Sanofi Company (25) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · Sanofi (4) · U.S. Army Medical Research and Development Command (3) · National University Hospital, Singapore (2) · University of the Philippines (2) · Oxford University Clinical Research Unit, Vietnam (2) · Mahidol University (1)

What is being tested here

Drugs under test in Severe Dengue studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Dexamethasone212
Acetylcysteine111
Baricitinib111
Interleukin 1 Receptor Antagonist Protein001
Human plasma001
Ribavirin011
Montelukast011
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18011
Human papillomavirus vaccine, L1 type 16, 18011
Yellow Fever Vaccine011

Coming up

1phase 3 study under way
3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Who these studies take

Of the 4 Severe Dengue studies recruiting now, 2 (50%) set no upper age limit and 1 (25%) stop at 75 or younger. 2 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (50%) take healthy volunteers.

Recruiting studies that take each age, of 4
AgeWomenMen
102 (50%)2 (50%)
184 (100%)4 (100%)
303 (75%)3 (75%)
403 (75%)3 (75%)
503 (75%)3 (75%)
653 (75%)3 (75%)
753 (75%)3 (75%)
853 (75%)3 (75%)

Across all 65 studies, recruiting or not: 82% stop at 75 or younger and 80% at 65; 52% take children; 2% are for women only and 0% for men only; 75% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Severe Dengue studies take

Of 13 phase 2 interventional studies under Severe Dengue, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 224 mo20–47 · 13 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 65. Browse all 65 → or search them.